Explore a little further

stock performance

Stories and perspectives from Daytrade News.

From Daytrade News

12 stories shown · Newest added
Daytrade News

AbbVie Stock Performance and Risks Linked to SKYRIZI Sales

AbbVie is nearing its 52-week high, driven by strong sales of SKYRIZI, its psoriasis and Crohn's disease treatment. However, potential risks to its stock price arise from market competition, pricing negotiations, and patent expirations. The company reported nearly $17 billion in…

More perspectives

Across our publications

A selection of related stories